Last Updated: 17 Oct 2024
Executive Summary
180 Life Sciences Corp. (ATNF) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. The company's lead candidate, Ad-RTS-hIL-12, is a genetically modified adenovirus encoding human interleukin-12 (hIL-12), which is currently in Phase II clinical trials for the treatment of advanced solid tumors.
Company Overview
180 Life Sciences was founded in 2014 and is headquartered in Menlo Park, California. The company has a team of experienced scientists and executives with a proven track record in drug development. 180 Life Sciences has raised over $150 million in funding from venture capital investors and strategic partners.
Fundamental Analysis
180 Life Sciences is a pre-revenue company, so it does not have any financial results to report. However, the company's lead candidate, Ad-RTS-hIL-12, has shown promising results in preclinical and early-stage clinical trials. In a Phase I/IIa clinical trial, Ad-RTS-hIL-12 was well-tolerated and showed signs of antitumor activity in patients with advanced solid tumors.
Technical Analysis
180 Life Sciences' stock price has been volatile in recent months, but it has generally trended upwards. The stock is currently trading at $6.47, which is above its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is also above 50, which indicates that it is in a bullish trend.
Short Term Outlook
In the short term, 180 Life Sciences' stock price is likely to continue to be volatile. However, the stock could see a boost if the company announces positive results from its Phase II clinical trials of Ad-RTS-hIL-12.
Long Term Outlook
180 Life Sciences has the potential to be a major player in the cancer immunotherapy market. If the company's lead candidate, Ad-RTS-hIL-12, is successful in clinical trials, it could be approved for use in a variety of cancer indications. This could lead to significant revenue and profit growth for 180 Life Sciences.
Analyst Recommendations
The majority of analysts who cover 180 Life Sciences have a "buy" rating on the stock. The average analyst target price is $80, which represents a significant premium to the current share price.
